All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
2.14 [0.70 ; 6.58 ] Sekine (PLACOVID), 2021 1 0% 160 NA not evaluable death D28detailed results Abuhasira, 2021 0.72 [0.23; 2.24]
AlQahtani, 2020 0.47 [0.04; 5.69]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
Jamaati, 2021 1.19 [0.38; 3.72]
Li, 2020 0.59 [0.22; 1.59]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RECOVER, 2021 1.09 [0.38; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shu, 2020 0.38 [0.02; 8.14]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
1.07 [0.86 ; 1.34 ] Abuhasira, 2021, AlQahtani, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, Jamaati, 2021, Li, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 14 0% 1,444 moderate low deathsdetailed results AlQahtani, 2020 0.47 [0.04; 5.69]
Cao, 2020 0.71 [0.36; 1.40]
CAPSID, 2021 0.84 [0.28; 2.50]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Jamaati, 2021 1.19 [0.38; 3.72]
Li, 2020 0.59 [0.22; 1.59]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Rasheed, 2020 0.13 [0.01; 1.09]
RECOVER, 2021 1.09 [0.38; 3.13]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shu, 2020 0.38 [0.02; 8.14]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.88 [0.79 ; 0.99 ] AlQahtani, 2020, Cao, 2020, CAPSID, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DEXA-COVID19, 2020, Jamaati, 2021, Li, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shu, 2020, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 28 4% 6,254 moderate low deaths (time to event analysis only)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
Talaschian, 2021 1.25 [0.30; 5.14]
0.89 [0.66 ; 1.20 ] COALITION II Covid-19 Brazil (Furtado), 2020, CP-COVID-19, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Talaschian, 2021 5 47% 1,588 moderate not evaluable clinical deteriorationdetailed results CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
Shu, 2020 0.27 [0.01; 5.58]
0.63 [0.45 ; 0.88 ] CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Shu, 2020 4 0% 575 moderate not evaluable clinical improvementdetailed results Cao, 2020 1.31 [0.94; 1.83]
CAPSID, 2021 1.58 [0.71; 3.49]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Li, 2020 1.40 [0.79; 2.49]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 10.27 [1.17; 90.18]
1.29 [0.95 ; 1.75 ] Cao, 2020, CAPSID, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Li, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shu, 2020 10 74% 2,067 moderate low clinical improvement (14-day)detailed results Cao, 2020 1.94 [1.09; 3.48]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
Li, 2020 2.27 [0.90; 5.72]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
Shu, 2020 10.27 [1.17; 90.18]
1.11 [0.72 ; 1.70 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Li, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Shu, 2020 6 73% 1,791 moderate serious clinical improvement (28-day)detailed results Abuhasira, 2021 1.70 [0.52; 5.49]
Cao, 2020 1.59 [0.84; 3.03]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
Li, 2020 1.42 [0.65; 3.10]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
1.23 [0.83 ; 1.82 ] Abuhasira, 2021, Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Li, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020 7 58% 1,024 moderate serious clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
Li, 2020 0.98 [0.27; 3.58]
Shu, 2020 6.72 [1.50; 30.07]
1.74 [0.70 ; 4.33 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Li, 2020, Shu, 2020 4 62% 740 moderate not evaluable clinical improvement (time to event analysis only)detailed results Abuhasira, 2021 1.22 [0.70; 2.14]
Cao, 2020 1.31 [0.94; 1.83]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Li, 2020 1.40 [0.79; 2.49]
Rahmani, 2020 3.41 [1.33; 8.73]
1.48 [1.16 ; 1.89 ] Abuhasira, 2021, Cao, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Li, 2020, Rahmani, 2020 6 8% 313 moderate not evaluable death or ventilationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Veiga, 2021 1.54 [0.65; 3.63]
0.93 [0.35 ; 2.49 ] CORIMUNO-TOCI-1 (Group 1), 2020, Veiga, 2021 2 63% 260 moderate not evaluable hospital dischargedetailed results Rahmani, 2020 3.44 [0.64; 18.49]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
0.80 [0.55 ; 1.16 ] Rahmani, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 3 56% 1,117 moderate not evaluable mechanical ventilationdetailed results Abuhasira, 2021 1.62 [0.41; 6.39]
AlQahtani, 2020 0.67 [0.22; 2.02]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Jamaati, 2021 1.38 [0.45; 4.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Shu, 2020 0.59 [0.02; 14.04]
Tabarsi, 2020 1.49 [0.59; 3.78]
1.03 [0.66 ; 1.62 ] Abuhasira, 2021, AlQahtani, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Jamaati, 2021, Rahmani, 2020, Shu, 2020, Tabarsi, 2020 8 0% 425 moderate not evaluable mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
0.66 [0.25 ; 1.72 ] CP-COVID-19, 2021 1 0% 100 NA not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
Tabarsi, 2020 2.33 [0.45; 12.00]
3.53 [1.19 ; 10.46 ] Jamaati, 2021, Tabarsi, 2020 2 0% 134 moderate not evaluable viral clearance detailed results CP-COVID-19, 2021 1.12 [0.16; 7.84]
Raman, 2021 36.42 [10.85; 122.18]
6.97 [0.23 ; 210.35 ] CP-COVID-19, 2021, Raman, 2021 2 89% 200 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Raman, 2021 36.42 [10.85; 122.18]
7.68 [0.34 ; 173.70 ] CP-COVID-19, 2021, Raman, 2021 2 90% 200 moderate not evaluable ICU admissiondetailed results Abuhasira, 2021 1.96 [0.51; 7.52]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Rahmani, 2020 0.37 [0.14; 1.00]
Tabarsi, 2020 0.56 [0.18; 1.74]
0.69 [0.43 ; 1.10 ] Abuhasira, 2021, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020, Tabarsi, 2020 6 0% 394 moderate not evaluable recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.16 [0.86 ; 1.55 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021, Talaschian, 2021, Veiga, 2021 10 37% 4,343 moderate low superinfectiondetailed results Rahmani, 2020 0.18 [0.02; 1.59]
0.18 [0.02 ; 1.59 ] Rahmani, 2020 1 0% 66 NA not evaluable adverse eventsdetailed results Raman, 2021 1.36 [0.56; 3.30]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shu, 2020 2.48 [0.05; 132.54]
Veiga, 2021 1.65 [0.81; 3.37]
1.14 [0.92 ; 1.43 ] Raman, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Veiga, 2021 4 0% 430 moderate not evaluable long QTdetailed results COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
0.90 [0.56 ; 1.43 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable renal impairmentdetailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
1.44 [0.99 ; 2.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 06:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290